Atossa Therapeutics, Inc.
General ticker "ATOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $111.2M (TTM average)
Atossa Therapeutics, Inc. follows the US Stock Market performance with the rate: 32.7%.
Estimated limits based on current volatility of 3.4%: low 0.71$, high 0.76$
Factors to consider:
- Total employees count: 12 (+9.1%) as of 2023
- Top business risk factors: Insufficient funding, Operating losses, Dependence on external financing, Uncertain profitability, Operational and conduct risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.65$, 1.82$]
- 2025-12-31 to 2026-12-31 estimated range: [0.46$, 1.36$]
Financial Metrics affecting the ATOS estimates:
- Positive: with PPE of -4.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.85 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -100 <= -0.75
- Positive: Shareholder equity ratio, % of 93.50 > 63.39
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.02 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ATOS quotes
Long-term ATOS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $27.69MM | $31.38MM | $27.62MM |
| Operating Income | $-27.69MM | $-31.38MM | $-27.62MM |
| Non-Operating Income | $0.73MM | $1.28MM | $2.12MM |
| R&D Expense | $15.08MM | $17.33MM | $14.12MM |
| Income(Loss) | $-26.96MM | $-30.09MM | $-25.50MM |
| Profit(Loss)* | $-26.96MM | $-30.09MM | $-25.50MM |
| Stockholders Equity | $117.96MM | $91.02MM | $71.48MM |
| Inventory | $5.25MM | $1.49MM | $0.00MM |
| Assets | $123.53MM | $96.25MM | $76.44MM |
| Operating Cash Flow | $-20.76MM | $-20.94MM | $-21.03MM |
| Capital expenditure | $0.03MM | $0.01MM | $0.02MM |
| Investing Cash Flow | $-4.73MM | $-0.01MM | $-0.02MM |
| Financing Cash Flow | $0.00MM | $-1.48MM | $3.67MM |
| Earnings Per Share** | $-0.21 | $-0.24 | $-0.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.